Gilead CEO Daniel O'Day (Credit: Georgios Kefalas/AP)
November 7, 2019 07:21 AM ESTUpdated 10:36 AM
Pharma
FDA+

HHS is tak­ing Gilead to court, seek­ing dam­ages for in­fring­ing gov­ern­ment HIV patents

Natalie Grover

Reporter

Gilead ear­li­er this year fired an open­ing sal­vo by march­ing to the US Patent and Trade­mark Of­fice and re­quest­ing a re­view of the

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times